blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4228645

EP4228645 - COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  21.07.2023
Database last updated on 25.09.2024
FormerThe international publication has been made
Status updated on  22.04.2022
Most recent event   Tooltip24.09.2024Supplementary search reportpublished on 23.10.2024 [2024/43]
Applicant(s)For all designated states
Recurium IP Holdings, LLC
10275 Science Center Drive, Suite 200
San Diego, CA 92121 / US
[2023/34]
Inventor(s)01 / SAMATAR, Ahmed, Abdi
San Diego, California 92121 / US
02 / DONATE, Fernando
San Diego, California 92121 / US
03 / IZADI, Hooman
San Diego, California 92121 / US
04 / PINCHMAN, Joseph, Robert
San Diego, California 92121 / US
05 / BUNKER, Kevin, Duane
San Diego, California 92121 / US
06 / HUANG, Peter, Qinhua
San Diego, California 92121 / US
 [2023/34]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2023/34]
Application number, filing date21881307.913.10.2021
[2023/34]
WO2021US71840
Priority number, dateUS202063092958P16.10.2020         Original published format: US 202063092958 P
[2023/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022082180
Date:21.04.2022
Language:EN
[2022/16]
Type: A1 Application with search report 
No.:EP4228645
Date:23.08.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 21.04.2022 takes the place of the publication of the European patent application.
[2023/34]
Search report(s)International search report - published on:AU21.04.2022
(Supplementary) European search report - dispatched on:EP23.09.2024
ClassificationIPC:A61K31/496, A61K31/5355, A61K31/7068, A61K31/4184, A61K31/69, A61P35/00, A61P35/02, A61K39/05, A61K31/706, A61K31/7048, A61K31/704, A61K31/675, A61K31/573, A61K31/497, A61K31/475, A61K31/5377, A61K31/555, A61K38/05
[2024/43]
CPC:
A61P35/00 (EP,AU); A61K31/496 (AU,US); A61K31/4184 (EP,AU);
A61K31/475 (EP); A61K31/497 (EP); A61K31/5377 (EP,US);
A61K31/555 (EP); A61K31/573 (EP,US); A61K31/675 (EP);
A61K31/69 (AU); A61K31/704 (EP); A61K31/7048 (EP);
A61K31/706 (EP,AU); A61K31/7068 (EP,AU); A61K38/05 (EP);
A61K45/06 (US); A61P35/02 (EP,AU,US); A61K2300/00 (AU) (-)
C-Set:
A61K31/4184, A61K2300/00 (EP,AU);
A61K31/475, A61K2300/00 (EP);
A61K31/496, A61K2300/00 (AU);
A61K31/497, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP);
A61K31/555, A61K2300/00 (EP);
A61K31/573, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K31/69, A61K2300/00 (AU);
A61K31/7048, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP,AU);
A61K31/706, A61K2300/00 (AU,EP);
A61K38/05, A61K2300/00 (EP)
(-)
Former IPC [2023/34]A61K31/496, A61K31/5355, A61K31/7068, A61K31/4184, A61K31/69, A61P35/00, A61P35/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/34]
TitleGerman:KOMBINATIONEN VON BCL-2-INHIBITOREN MIT CHEMOTHERAPEUTISCHEN MITTELN[2023/34]
English:COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS[2023/34]
French:COMBINAISONS D'INHIBITEURS DE BCL-2 AVEC DES AGENTS CHIMIOTHÉRAPEUTIQUES[2023/34]
Entry into regional phase15.05.2023National basic fee paid 
15.05.2023Search fee paid 
15.05.2023Designation fee(s) paid 
15.05.2023Examination fee paid 
Examination procedure15.05.2023Examination requested  [2023/34]
Fees paidRenewal fee
13.09.2023Renewal fee patent year 03
12.09.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2019139899  (ZENO ROYALTIES & MILESTONES LLC [US]);
 [Y]WO2019139900  (ZENO ROYALTIES & MILESTONES LLC [US]);
 [Y]WO2020024826  (ASCENTAGE PHARMA SUZHOU CO LTD [CN]);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.